List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Measles - Overview
Measles - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Measles - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Measles - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Co Ltd
Enesi Pharma Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
Micron Biomedical Inc
Panacea Biotec Ltd
Sinovac Biotech Ltd
Univercells SA
Vaxxas Inc
VBI Vaccines Inc
Measles - Drug Profiles
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella + varicella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + mumps + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles + rubella) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERDRP-0519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
measles vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
measles vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Measles - Dormant Projects
Measles - Product Development Milestones
Featured News & Press Releases
Sep 01, 2020: Micron Biomedical progresses with clinical evaluation of its technology for measles-rubella vaccination
Mar 18, 2020: Vaxxas awarded US$5 million grant for clinical study of measles and rubella vaccination
Nov 30, 2019: Vaxxas was awarded research and development fund of USD 4,997,693 from Bill & Melinda Gates Foundation
Nov 30, 2016: Vaxxas was awarded research and development fund of USD 4,479,552 from Bill & Melinda Gates Foundation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Measles, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Measles - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
Measles - Pipeline by Biological E Ltd, H2 2020
Measles - Pipeline by Cadila Healthcare Ltd, H2 2020
Measles - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Measles - Pipeline by Enesi Pharma Ltd, H2 2020
Measles - Pipeline by GlaxoSmithKline Plc, H2 2020
Measles - Pipeline by Indian Immunologicals Ltd, H2 2020
Measles - Pipeline by Micron Biomedical Inc, H2 2020
Measles - Pipeline by Panacea Biotec Ltd, H2 2020
Measles - Pipeline by Sinovac Biotech Ltd, H2 2020
Measles - Pipeline by Univercells SA, H2 2020
Measles - Pipeline by Vaxxas Inc, H2 2020
Measles - Pipeline by VBI Vaccines Inc, H2 2020
Measles - Dormant Projects, H2 2020

List of Figures
Number of Products under Development for Measles, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Beijing Minhai Biotechnology Co Ltd
• Biological E Ltd
• Cadila Healthcare Ltd
• Daiichi Sankyo Co Ltd
• Enesi Pharma Ltd
• GlaxoSmithKline Plc
• Indian Immunologicals Ltd
• Micron Biomedical Inc
• Panacea Biotec Ltd
• Sinovac Biotech Ltd
• Univercells SA
• Vaxxas Inc
• VBI Vaccines Inc